Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.
Tirzepatide and semaglutide affect blood pressure differently—one reduces hypertension risk substantially but may cause low blood pressure at higher doses, while the other stays neutral.
The largest meta-analysis comparing BP-related safety of tirzepatide vs semaglutide (32 RCTs, 47,332 participants) found tirzepatide reduces hypertension risk 60% but doubles dose-dependent hypotension risk, while semaglutide is BP-neutral. These distinct hemodynamic profiles provide immediately actionable guidance for prescribers choosing between agents in patients with baseline cardiovascular risk.
What the study was
- Study design
- Systematic review and meta-analysis of 32 RCTs; random-effects model; search through September 2025.
- Population
- 47,332 participants with T2DM or obesity in 32 RCTs.
- Sample size
- 47332
- Category
- Diagnostics
- Maturity
- Potentially Practice-Changing
- Journal
- Endocrine
Why it surfaced
Largest BP-focused meta-analysis for tirzepatide vs semaglutide (32 RCTs, n=47,332); tirzepatide hypotension signal is a new prescribing safety flag. Directly informs clinical decisions for the most widely used obesity/T2DM agents.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.